Compounds > 3,4-dihydroxyphenylacetic acid

3,4-dihydroxyphenylacetic acid and cgp 56999a

3,4-dihydroxyphenylacetic acid has been researched along with cgp 56999a in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Enna, SJ; Reisman, SA; Stanford, JA	1

Other Studies

1 other study(ies) available for 3,4-dihydroxyphenylacetic acid and cgp 56999a

Article	Year
CGP 56999A, a GABA(B) receptor antagonist, enhances expression of brain-derived neurotrophic factor and attenuates dopamine depletion in the rat corpus striatum following a 6-hydroxydopamine lesion of the nigrostriatal pathway. Neuroscience letters, 2006, Oct-02, Volume: 406, Issue:1-2 Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain-Derived Neurotrophic Factor; Corpus Striatum; Denervation; Disease Models, Animal; Dopamine; GABA Antagonists; GABA-B Receptor Antagonists; Gene Expression; Male; Neural Inhibition; Neural Pathways; Oxidopamine; Parkinsonian Disorders; Phosphinic Acids; Rats; Rats, Inbred F344; Receptors, GABA-B; Substantia Nigra; Sympatholytics; Synaptic Transmission; Treatment Outcome; Up-Regulation	2006

Article

Year

CGP 56999A, a GABA(B) receptor antagonist, enhances expression of brain-derived neurotrophic factor and attenuates dopamine depletion in the rat corpus striatum following a 6-hydroxydopamine lesion of the nigrostriatal pathway.

Neuroscience letters, 2006, Oct-02, Volume: 406, Issue:1-2

Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain-Derived Neurotrophic Factor; Corpus Striatum; Denervation; Disease Models, Animal; Dopamine; GABA Antagonists; GABA-B Receptor Antagonists; Gene Expression; Male; Neural Inhibition; Neural Pathways; Oxidopamine; Parkinsonian Disorders; Phosphinic Acids; Rats; Rats, Inbred F344; Receptors, GABA-B; Substantia Nigra; Sympatholytics; Synaptic Transmission; Treatment Outcome; Up-Regulation

2006